Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225843867> ?p ?o ?g. }
- W4225843867 abstract "Background A variety of minimally invasive surgical approaches are available as an alternative to transurethral resection of the prostate (TURP) for management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Prostatic arterial embolization (PAE) is a relatively new, minimally invasive treatment approach. Objectives To assess the effects of PAE compared to other procedures for treatment of LUTS in men with BPH. Search methods We performed a comprehensive search the Cochrane Library, MEDLINE, Embase, three other databases, trials registries, other sources of grey literature, and conference proceedings with no restrictions on language of publication or publication status, up to 8 November 2021. Selection criteria We included parallel‐group randomized controlled trials (RCTs), as well as non‐randomized studies (NRS, limited to prospective cohort studies with concurrent comparison groups) enrolling men over the age of 40 years with LUTS attributed to BPH undergoing PAE versus TURP or other surgical interventions. Data collection and analysis Two review authors independently classified studies for inclusion or exclusion and abstracted data from the included studies. We performed statistical analyses by using a random‐effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We used GRADE guidance to rate the certainty of evidence of RCTs and NRSs. Main results We found data to inform two comparisons: PAE versus TURP (six RCTs and two NRSs), and PAE versus sham (one RCT). Mean age was 66 years, International Prostate Symptom Score (IPSS) was 22.8, and prostate volume of participants was 72.8 mL. This abstract focuses on the comparison of PAE versus TURP as the primary topic of interest. Prostatic arterial embolization versus transurethral resection of the prostate We included six RCTs and two NRSs with short‐term (up to 12 months) follow‐up, and two RCTs and one NRS with long‐term follow‐up (13 to 24 months). Short‐term follow‐up: based on RCT evidence, there may be little to no difference in urologic symptom score improvement measured by the International Prostatic Symptom Score (IPSS) on a scale from 0 to 35, with higher scores indicating worse symptoms (mean difference [MD] 1.72, 95% confidence interval [CI] –0.37 to 3.81; 6 RCTs, 360 participants; I² = 78%; low‐certainty evidence). There may be little to no difference in quality of life as measured by the IPSS‐quality of life question on a scale from 0 to 6, with higher scores indicating worse quality of life between PAE and TURP, respectively (MD 0.28, 95% CI –0.28 to 0.84; 5 RCTs, 300 participants; I² = 63%; low‐certainty evidence). While we are very uncertain about the effects of PAE on major adverse events (risk ratio [RR] 0.75, 95% CI 0.19 to 2.97; 4 RCTs, 250 participants; I² = 24%; very low‐certainty evidence), PAE likely increases retreatments (RR 3.20, 95% CI 1.41 to 7.27; 4 RCTs, 303 participants; I² = 0%; moderate‐certainty evidence). PAE may make little to no difference in erectile function measured by the International Index of Erectile Function‐5 on a scale from 1 to 25, with higher scores indicating better function (MD –0.50 points, 95% CI –5.88 to 4.88; 2 RCTs, 120 participants; I² = 68%; low‐certainty evidence). Based on NRS evidence, PAE may reduce the occurrence of ejaculatory disorders (RR 0.51, 95% CI 0.35 to 0.73; 1 NRS, 260 participants; low‐certainty evidence). Long‐term follow‐up: based on RCT evidence, PAE may result in little to no difference in urologic symptom scores (MD 2.58 points, 95% CI –1.54 to 6.71; 2 RCTs, 176 participants; I² = 73%; low‐certainty evidence) and quality of life (MD 0.50 points, 95% CI –0.03 to 1.04; 2 RCTs, 176 participants; I² = 29%; low‐certainty evidence). We are very uncertain about major adverse events (RR 0.91, 95% CI 0.20 to 4.05; 2 RCTs, 206 participants; I² = 72%; very low‐certainty evidence). PAE likely increases retreatments (RR 3.80, 95% CI 1.32 to 10.93; 1 RCT, 81 participants; moderate‐certainty evidence). While PAE may result in little to no difference in erectile function (MD 3.09 points, 95% CI –0.76 to 6.94; 1 RCT, 81 participants; low‐certainty evidence), PAE may reduce the occurrence of ejaculatory disorders (RR 0.67, 95% CI 0.45 to 0.98; 1 RCT, 50 participants; low‐certainty evidence). Authors' conclusions Compared to TURP, PAE may provide similar improvement in urologic symptom scores and quality of life. While we are very uncertain about major adverse events, PAE likely increases retreatment rates. While erectile function may be similar, PAE may reduce ejaculatory disorders. Certainty of evidence for the outcomes of this review was low or very low except for retreatment (moderate‐certainty evidence), signaling that our confidence in the reported effect size is limited or very limited, and that this topic should be better informed by future research." @default.
- W4225843867 created "2022-05-05" @default.
- W4225843867 creator A5001861927 @default.
- W4225843867 creator A5003227309 @default.
- W4225843867 creator A5014757964 @default.
- W4225843867 creator A5018863839 @default.
- W4225843867 creator A5036514742 @default.
- W4225843867 creator A5044107299 @default.
- W4225843867 creator A5067816501 @default.
- W4225843867 creator A5078001562 @default.
- W4225843867 date "2022-03-29" @default.
- W4225843867 modified "2023-09-27" @default.
- W4225843867 title "Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia" @default.
- W4225843867 cites W1523669219 @default.
- W4225843867 cites W1890241494 @default.
- W4225843867 cites W1927668539 @default.
- W4225843867 cites W1942438727 @default.
- W4225843867 cites W1969351388 @default.
- W4225843867 cites W1979837745 @default.
- W4225843867 cites W1987730025 @default.
- W4225843867 cites W1992683171 @default.
- W4225843867 cites W1994976193 @default.
- W4225843867 cites W2001432092 @default.
- W4225843867 cites W2002004951 @default.
- W4225843867 cites W2009567938 @default.
- W4225843867 cites W2020568537 @default.
- W4225843867 cites W2021505568 @default.
- W4225843867 cites W2050440257 @default.
- W4225843867 cites W2050675379 @default.
- W4225843867 cites W2068706053 @default.
- W4225843867 cites W2085582807 @default.
- W4225843867 cites W2086240335 @default.
- W4225843867 cites W2086561958 @default.
- W4225843867 cites W2090132603 @default.
- W4225843867 cites W2092630235 @default.
- W4225843867 cites W2096998881 @default.
- W4225843867 cites W2099286969 @default.
- W4225843867 cites W2104675861 @default.
- W4225843867 cites W2120767646 @default.
- W4225843867 cites W2125435699 @default.
- W4225843867 cites W2126629865 @default.
- W4225843867 cites W2126930838 @default.
- W4225843867 cites W2132697170 @default.
- W4225843867 cites W2134236426 @default.
- W4225843867 cites W2138100694 @default.
- W4225843867 cites W2144115671 @default.
- W4225843867 cites W2151672345 @default.
- W4225843867 cites W2152788789 @default.
- W4225843867 cites W2156607742 @default.
- W4225843867 cites W2159157945 @default.
- W4225843867 cites W2164636380 @default.
- W4225843867 cites W2300522059 @default.
- W4225843867 cites W2325439446 @default.
- W4225843867 cites W2329509397 @default.
- W4225843867 cites W2330293894 @default.
- W4225843867 cites W2412543183 @default.
- W4225843867 cites W2483800985 @default.
- W4225843867 cites W2489411894 @default.
- W4225843867 cites W2514123397 @default.
- W4225843867 cites W2531269403 @default.
- W4225843867 cites W2550223574 @default.
- W4225843867 cites W2556924103 @default.
- W4225843867 cites W2567362164 @default.
- W4225843867 cites W2567655989 @default.
- W4225843867 cites W2588681363 @default.
- W4225843867 cites W2604282950 @default.
- W4225843867 cites W2616209239 @default.
- W4225843867 cites W2617583434 @default.
- W4225843867 cites W2729937958 @default.
- W4225843867 cites W2753663387 @default.
- W4225843867 cites W2765277689 @default.
- W4225843867 cites W2767956433 @default.
- W4225843867 cites W2770733749 @default.
- W4225843867 cites W2776799423 @default.
- W4225843867 cites W2789842800 @default.
- W4225843867 cites W2792308249 @default.
- W4225843867 cites W2792677358 @default.
- W4225843867 cites W2796362720 @default.
- W4225843867 cites W2797131700 @default.
- W4225843867 cites W2808328087 @default.
- W4225843867 cites W2809631697 @default.
- W4225843867 cites W2891881408 @default.
- W4225843867 cites W2895183991 @default.
- W4225843867 cites W2895557395 @default.
- W4225843867 cites W2902260460 @default.
- W4225843867 cites W2903145770 @default.
- W4225843867 cites W2906479416 @default.
- W4225843867 cites W2911276811 @default.
- W4225843867 cites W2916841405 @default.
- W4225843867 cites W2922319264 @default.
- W4225843867 cites W2924286167 @default.
- W4225843867 cites W2973049821 @default.
- W4225843867 cites W2980479151 @default.
- W4225843867 cites W2991846600 @default.
- W4225843867 cites W2991986594 @default.
- W4225843867 cites W2994267424 @default.
- W4225843867 cites W3014246102 @default.
- W4225843867 cites W3020783400 @default.
- W4225843867 cites W3022903699 @default.
- W4225843867 cites W3120006155 @default.